Skip to main content
Skip to main content
Back to Grand Rounds
Grand RoundsWeekly Evidence Brief

Rheumatology

Edition

30-Second Takeaway

  • Non-TNFi biologics in RA and RA-ILD show higher pneumonia and mortality despite similar ILD incidence across DMARDs.
  • GCA substantially elevates aortic and large-vessel event risk, especially during periods of active disease.
  • Men with primary Sjögren’s have markedly higher mortality and malignancy risk, warranting tighter surveillance and counseling.
  • Excess weight in spondyloarthritis links to higher btDMARD burden, worse function, and greater work and activity impairment.
  • RA is associated with albuminuric CKD at preserved eGFR, supporting routine albuminuria screening alongside nephrotoxic drug monitoring.

Week ending January 17, 2026

New data on RA-ILD therapy, vasculitis cardiovascular risk, Sjögren’s prognosis, and comorbidities in RA, SpA, and osteoporosis

Non-TNFi biologics in RA and RA-ILD: higher pneumonia and mortality at similar ILD risk

SEMINARS IN ARTHRITIS AND RHEUMATISMJan 15, 2026

This nationwide Korean cohort included 26,120 RA patients, with 641 RA-ILD cases and 209,852 treatment episodes across csDMARDs and advanced therapies. Adjusted ILD incidence and ILD-related hospitalizations were similar across TNFi, non-TNFi biologics, JAK inhibitors, and csDMARDs, including in RA-ILD. Non-TNFi biologics were associated with higher risks of hospitalization, serious infection, and all-cause mortality versus csDMARDs in both RA and RA-ILD. Pneumonia-related hospitalizations and recurrences were consistently higher with non-TNFi biologics, whereas TNFi and JAK inhibitors showed no such signal. MACE risk did not differ across DMARD classes, underscoring pneumonia and infection as the main safety concern with non-TNFi biologics.

GCA markedly raises aortic and vascular event risk beyond background comorbidity

EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGYJan 15, 2026

This French nationwide study followed 23,193 incident GCA patients aged at least 50 years, matched to general and hospitalized cohorts. Compared with the general population, GCA patients had markedly higher risks of aortic events, MACE, PAD, and visceral artery events. Versus a comorbidity-matched hospitalized cohort, risks of aortic, PAD, and visceral artery events remained elevated, while MACE risk was similar. Periods of active GCA were associated with nearly doubled MACE risk, linking inflammatory activity to major cardiovascular events. These findings support aggressive control of GCA activity, systematic cardiovascular risk management, and selective large-vessel imaging surveillance.

Brain–sympathetic circuit restrains articular cartilage regeneration in osteoarthritis

ANNALS OF THE RHEUMATIC DISEASESJan 15, 2026

This mechanistic study mapped a brain–cartilage circuit regulating joint cartilage regeneration in human and mouse osteoarthritis models. Activity in the hypothalamic paraventricular nucleus correlated with OA symptom burden and synovial fluid norepinephrine levels in patients. Tracing and neuromodulation experiments revealed a PVNCRH–sympathetic synovial nerve circuit that limits regeneration via norepinephrine signaling through β2-adrenergic receptors (ADRB2) on Proteoglycan 4+ cells. Inhibiting this circuit favored formation of stable mature articular cartilage instead of fibrocartilage, enhancing regeneration in experimental models. An ADRB2 inverse agonist prevented degradation in human cartilage explants, suggesting neuromodulatory and adrenergic targets for disease-modifying OA strategies.

References

Numbered in order of appearance. Click any reference to view details.

Additional Reads

Optional additional studies from this edition.

Edition context

Clinical signal

  • DMARD choice in RA and RA-ILD should factor pneumonia and mortality risks with non-TNFi biologics, not only ILD progression concerns.
  • Inflammation control plus structured cardiovascular risk and imaging strategies are central to reducing vascular events in GCA.
  • Sex-specific risk stratification in primary Sjögren’s can guide intensity of monitoring for death, malignancy, and organ complications.